Cholangiocarcinoma in primary sclerosing cholangitis: K-ras mutations and Tp53 dysfunction are implicated in the neoplastic development

Journal of Hepatology

Volumn 32, Issue 3, 2000, Pages 374-380

  Boberg, Kirsten Muri ^a   Schrumpf, Erik ^a   Bergquist, Annika ^b   Broomé, Ulrika ^b   Pares, Albert ^c   Remotti, Helen ^d   Schjölberg, Aasa ^e   Spurkland, Anne ^a   Clausen, Ole Petter Fraas ^e  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c HOSPITAL CLÍNIC   (Spain)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e UNIVERSITY OF OSLO   (Norway)

Author keywords

Cholangiocarcinoma; K ras mutations; Ki 67 immunoreactivity; P53 protein; Primary sclerosing cholangitis; Tumor markers

Indexed keywords

KI 67 ANTIGEN; PROTEIN P53;

ADOLESCENT; ADULT; ANTIGEN EXPRESSION; ARTICLE; BILE DUCT CARCINOMA; BILE DUCT OBSTRUCTION; CHOLANGIOGRAPHY; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; GENE AMPLIFICATION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER CARCINOGENESIS; LIVER TRANSPLANTATION; MALE; MALIGNANT TRANSFORMATION; NUCLEIC ACID BASE SUBSTITUTION; ONCOGENE K RAS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL;

EID: 0034053517     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(00)80386-4     Document Type: Article

References (34)

1. Wiesner RH, Grambsch PM, Dickson ER, Ludwig J, MacCarty RL, Hunter EB, et al. Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology. 10:1989;430-436.
2. Abu-Elmagd KM, Selby R, Iwatsuki S, Fung J, Tzakis A, Todo S, et al. Cholangiocarcinoma and sclerosing cholangitis: clinical characteristics and effect on survival after liver transplantation. Transplant Proc. 25:1993;1124-1125.
3. Schrumpf E, Abdelnoor M, Fausa O, Elgjo K, Jenssen E, Kolmannskog F. Risk factors in primary sclerosing cholangitis. J Hepatol. 21:1994;1061-1066.
4. Farges O, Malassagne B, Sebagh M, Bismuth H. Primary sclerosing cholangitis: liver transplantation or biliary surgery. Surgery. 117:1995;146-155.
5. Broomé U, Olsson R, Lööf L, Bodemar G, Hultcrantz R, Danielsson Å, et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut. 38:1996;610-615.
6. Rosen C, Nagorney DM, Wiesner RH, Coffey RJ Jr, LaRusso NF. Cholangiocarcinoma complicating primary sclerosing cholangitis. Ann Surg. 213:1991;21-25.
7. Broomé U, Eriksson LS. Assessment for liver transplantation in patients with primary sclerosing cholangitis. J Hepatol. 20:1994;654-659.
8. Barbacid M. ras genes. Annu Rev Biochem. 56:1987;779-827.
9. Bos JL. ras oncogenes in human cancer: a review. Cancer Res. 49:1989;4682-4689.
10. Fearon ER. K-ras gene mutation as a pathogenetic and diagnostic marker in human cancer. [editorial] J Natl Cancer Inst. 85:1993;1978-1980.
11. Tada M, Yokosuka O, Omata M, Ohto M, Isono K. Analysis of ras gene mutations in biliary and pancreatic tumors by polymerase chain reaction and direct sequencing. Cancer. 66:1990;930-935.
12. Watanabe M, Asaka M, Tanaka J, Kurosawa M, Kasai M, Miyazaki T. Point mutation of K-ras gene codon 12 in biliary tract tumors. Gastroenterology. 107:1994;1147-1153.
13. Levi S, Urbano-Ispizua A, Gill R, Thomas DM, Gilbertson J, Foster C, et al. Multiple K-ras codon 12 mutations in cholangiocarcinomas demonstrated with a sensitive polymerase chain reaction technique. Cancer Res. 51:1991;3497-3502.
14. Tada M, Omata M, Ohto M. High incidence of ras gene mutation in intrahepatic cholangiocarcinoma. Cancer. 69:1992;1115-1118.
15. Ohashi K, Tsutsumi M, Nakajima Y, Noguchi O, Okita S, Kitada H, et al. High rates of Ki-ras point mutation in both intra- and extrahepatic cholangiocarcinomas. Jpn J Clin Oncol. 24:1994;305-310.
16. Tsuda H, Satarug S, Bhudhisawasdi V, Kihana T, Sugimura T, Hirohashi S. Cholangiocarcinomas in Japanese and Thai patients: difference in etiology and incidence of point mutation of the c-Ki-ras proto-oncogene. Mol Carcinog. 6:1992;266-269.
17. Motojima K, Tsunoda T, Kanematsu T, Nagata Y, Urano T, Shiku H. Distinguishing pancreatic carcinoma from other periampullary carcinomas by analysis of mutations in the Kirsten-ras oncogene. Ann Surg. 214:1991;657-662.
18. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54:1994;4855-4878.
19. Darnton SJ. Demystified p53. J Clin Pathol Mol Pathol. 51:1998;248-253.
20. Kiba T, Tsuda H, Pairojkul C, Inoue S, Sugimura T, Hirohashi S. Mutations of the p53 tumor suppressor gene and the ras gene family in intrahepatic cholangiocellular carcinomas in Japan and Thailand. Mol Carcinog. 8:1993;312-318.
21. Ohashi K, Nakajima Y, Kanehiro H, Tsutsumi M, Taki J, Aomatsu Y, et al. Ki-ras mutations and p53 expressions in intrahepatic cholangiocarcinomas: relation to gross tumor morphology. Gastroenterology. 109:1995;1612-1617.
22. Rizzi PM, Ryder SD, Portmann B, Ramage JK, Naoumov NV, Williams R. p53 protein overexpression in cholangiocarcinoma arising in primary sclerosing cholangitis. Gut. 38:1996;265-268.
23. MacCarty RL, LaRusso NF, Wiesner RH, Ludwig J. Primary sclerosing cholangitis: findings on cholangiography and pancreatography. Radiology. 149:1983;39-44.
24. Breivik J, Meling GI, Spurkland A, Rognum TO, Gaudernack G. K-ras mutation in colorectal cancer: relation to patient age, sex and tumour location. Br J Cancer. 69:1994;367-371.
25. Norheim Andersen S, Breivik J, Løvig T, Meling GI, Gaudernack G, Clausen OPF, et al. K-ras mutations and HLA-DR expression in large bowel adenomas. Br J Cancer. 74:1996;99-108.
26. Clausen OPF, Lothe RA, Børresen-Dale A-L, De Angelis Å, Chen Y, Rognum TO, et al. Association of p53 accumulation with TP53 mutations, loss of heterozygosity at 17p13, and DNA ploidy status in 273 colorectal carcinomas. Diagn Mol Pathol. 7:1998;215-223.
27. Celli A, Que FG. Dysregulation of apoptosis in the cholangiopathies and cholangiocarcinoma. Semin Liver Dis. 18:1998;177-185.
28. Terada T, Shimizu K, Izumi R, Nakanuma Y. p53 expression in formalin-fixed, paraffin-embedded archival specimens of intrahepatic cholangiocarcinoma: retrieval of p53 antigenicity by microwave oven heating of tissue sections. Modern Pathology. 7:1994;249-252.
29. Symonds H, Krall L, Remington L, Saenz-Robles M, Lowe S, Jacks T, et al. p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell. 78:1994;703-711.
30. Vogelstein B, Fearon D, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 19:1988;525-532.
31. Yin J, Harpaz N, Tong Y, Huang Y, Laurin J, Greenwald BD, et al. p53 point mutations in dysplastic and cancerous ulcerative colitis lesions. Gastroenterology. 104:1993;1633-1639.
32. Van Laethem J-L, Bourgeois V, Parma J, Delhaye M, Cochaux P, Velu T, et al. Relative contribution of Ki-ras gene analysis and brush cytology during ERCP for the diagnosis of biliary and pancreatic diseases. Gastrointest Endosc. 47:1998;479-485.
33. Ito R, Tamura K, Ashida H, Nishiwaki M, Nishioka A, Yamamoto Y, et al. Usefulness of K-ras gene mutation at codon 12 in bile for diagnosing biliary strictures. Int J Oncol. 12:1998;1019-1023.
34. Kubicka S, Meier P, Flemming P, Kühnel F, Rudolph L, Manns M. High incidence of K-ras mutations in the bile fluids of patients with primary sclerosing cholangitis. J Hepatol. 30:(Suppl. 1):1999;58.